相关实验视频

Updated: Sep 14, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

在不同复发模式下分析非转移性子宫内膜癌的术后预后

Dong Yang¹, Xiaoli Zhang², Yini Tan³

¹Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.

Scientific reports

|July 22, 2025

概括

确定子宫内膜癌 (EC) 复发的高风险因素是关键. 诸如FIGO阶段,分子分类,淋巴血管空间入侵 (LVSI) 和吸烟史等因素显著影响整体生存率 (OS) 和无复发生存率 (RFS).

科学领域:

妇科瘤学妇科瘤学
癌症研究癌症研究
临床病理学临床病理学

背景情况:

子宫内膜癌 (EC) 复发和转移需要识别高风险因素,以改善患者分层和管理.
精确的临床策略对于改善EC患者的治疗结果至关重要.

研究的目的:

在I-III期子宫内膜癌患者中确定总生存 (OS) 和无复发生存 (RFS) 的独立风险因素.
分析预后因素,区分地方区域复发 (LR) 和预后不佳的复发 (PPR).

主要方法:

对336名I-III阶段EC患者的回顾性分析.
根据复发地点分类为没有复发 (NR),局部区域复发 (LR) 和预后不佳的复发 (PPR) 组.
统计分析以确定OS和RFS的独立风险因素,包括子组分析.

主要成果:

五年后的OS率为89.4% (NR),60.2% (LR) 和46.8% (PPR). 五年后的OS率为89.4% (NR),60.2% (LR) 和46.8% (PPR). 五年期RFS率为100% (NR),15.4% (LR) 和6.4% (PPR). 这三年间的RFS率均为100% (NR),15.4% (LR) 和6.4% (PPR).
五年OS和RFS的独立风险因素包括FIGO阶段,分子分类,淋巴血管空间入侵 (LVSI) 和吸烟史.
确定的特定因素:肌肉膜侵袭 (≥1/2) 和LR的大量LVSI;对于PPR的雌激素受体 (ER) 和孕激素受体 (PR) 阳性.

结论:

患有特定肌肉膜侵袭和LVSI水平的患者面临更高的LR风险.
阳性ER和PR状态与增加PPR风险有关.
这些已识别的因素对于预测EC患者预后和指导临床管理至关重要.

关键词:

宫内膜癌 (Endometrial carcinoma) 是一种子宫内膜癌.雌激素受体的受体是什么淋巴血管的空间入侵肌体的入侵肌体的入侵孕激素受体是什么? 孕激素受体是什么?

更多相关视频

Fertility Sparing Procedure using Carbon Dioxide Fiber Laser Vaporization of Ovarian Endometrioma

Fertility Sparing Procedure using Carbon Dioxide Fiber Laser Vaporization of Ovarian Endometrioma

Published on: July 6, 2022

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...